Market Intelligence, Clinical Progress, and High-Purity Reagents for Agonist and Bispecific Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for TNFRSF18 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TNFRSF18 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View TNFRSF18 Products |
| Gene Delivery | TNFRSF18 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. High titer (>10^8 TU/mL). |
View TNFRSF18 Products |
| Benchmark Ab | Anti-TNFRSF18 (Sequence of BMS-986156/TRX518/INCAGN1876) Recombinant positive control. |
View TNFRSF18 Products |
| Validator | TNFRSF18 siRNA Set For knockdown verification. |
View TNFRSF18 Products |
| Ligand Control | TNFSF18 (GITRL) ECD-Fc For competitive binding and blocking assays. |
View TNFSF18 Products |
| Related Target A | PDCD1 (PD-1) Synergistic immune checkpoint combination partner. |
View PDCD1 Products |
| Related Target B | TNFRSF4 (OX40) Parallel co-stimulatory receptor for broader T-cell activation. |
View TNFRSF4 Products |
| Related Target C | TNFRSF9 (4-1BB) Alternative TNFRSF costimulatory target for comparative agonist studies. |
View TNFRSF9 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Complex Membrane Clustering Requirements | Lentivirus available for generating stable HEK293/CHO cell lines to preserve native conformation. |
| Fc-Receptor Dependency Analysis | HEK293 Expressed (Native Glycosylation) ECD proteins for highly specific SPR/BLI binding assays. |
| Lack of Positive Controls | Clinical Benchmark Antibodies (Biosimilars) included with strictly verified theoretical MW. |
| Non-specific Binding / False Positives | Valid sequence-verified siRNA included for precise specificity checks in cellular assays. |
| Cross-species Toxicology (Cyno/Mouse) | Human/Mouse/Cyno ortholog proteins available with >95% purity; Sequence Verified for epitope conservation. |
| Receptor Internalization Dynamics | Lentivirus-based stable cell lines for live-cell imaging and internalization kinetics; Full-length native sequence. |
| Specificity vs. TNFRSF Subfamily | Homolog panel proteins (OX40, 4-1BB, CD40) strictly verified by mass spec for cross-reactivity screening. |
Live TNFRSF18/CD357 (GITR) R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for TNFRSF18 (GITR) therapeutics is evolving, with major players shifting focus from traditional monospecific agonist mAbs to advanced bispecific and conditionally active modalities. As first-generation therapies faced challenges with dose-limiting toxicities or suboptimal efficacy in the clinic, the next wave of R&D is targeting precise tumor-microenvironment (TME) activation and synergistic co-inhibition blockades. Key players include BMS (BMS-986156), Leap Therapeutics (TRX518), Incyte/Agenus (INCAGN1876), GSK (GSK4171276), and iTeos (EOS-448). The critical differentiator lies in epitope selection within Cysteine-Rich Domain 2 (CRD2), where clustering efficiency determines Treg depletion versus exhaustion.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Agonist Monoclonal Ab | BMS, Leap Therapeutics, Incyte, GSK, iTeos | Solid Tumors (NSCLC, Melanoma) | Receptor Clustering Assay (Need Lentivirus for Stable Cell Lines) |
| Bispecific (e.g., PD-1 x GITR) | Innovent Biologics, Agenus, BMS | Refractory Immunotherapy | Heterodimer Validation (Need High-Purity Cross-reactive Antigens) |
| Conditionally Active Abs | Various Biotechs | Metastatic Melanoma | pH-dependent Binding (Need Sequence-Verified ECD-Fc) |
| Fc-Engineered Agonist | Agenus, Shattuck Labs | Immunotherapy combos | FcγR Binding Assay (Need stable cell lines expressing Fc receptors) |
| ADC | Emerging preclinical | Treg-high tumors | Internalization Assay (Need full-length lentivirus lines) |
Molecular Differentiation & Assay Strategy
Key Differentiation Factors
- Epitope & Clustering: GITR agonist activity strictly depends on antibody-induced receptor trimerization/oligomerization. Optimal epitope is in CRD2, requiring spatial conformation for IgG cross-linking.
- Cross-species Reactivity: Toxicology studies require validation in Cynomolgus monkey (>95% sequence similarity) and mouse models. Key residues (e.g., Cys-76, Asp-95) are conserved across species.
- Fc Engineering: ADCC-enhanced (afucosylated) for Treg depletion; Fc-silent (LALA mutations) for pure signaling; pH-dependent Fc for TME-specific activation.
- Internalization Dynamics: ADC development requires assessment of receptor internalization rate; GITR internalizes slowly, requiring epitope-specific screening.
Critical Assay Needs
| Differentiation Factor | Required Assay | TarMart Solution |
|---|---|---|
| Agonist Activity | NF-κB reporter gene cell assay; Primary Treg suppression assay | TNFRSF18 Lentivirus for Jurkat-NFκB reporter cell lines |
| Epitope Mapping | Domain deletion mutant binding (CRD1/2/3 truncation) | Segmented ECD mutant proteins (CRD1-Fc, CRD2-Fc) |
| Cross-species | Cyno/Mouse/Human ortholog protein parallel SPR | Three-species ortholog proteins, >95% purity |
| Fc Function | FcγR binding (CD16a, CD32a) and ADCC reporter assays | Benchmark antibodies (e.g., INCAGN1876 sequence) as positive controls |
| Specificity Exclusion | TNFRSF subfamily cross-reactivity (OX40, 4-1BB, CD40, TNFR2) | Homolog protein panel (TNFRSF4, TNFRSF9), Mass Spec verified |
| Ligand Competition | GITRL blocking assay | TNFSF18 (GITRL) ECD-Fc as competitive reagent |